Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy
出版年份 2020 全文链接
标题
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy
作者
关键词
-
出版物
PROSTATE
Volume 80, Issue 4, Pages 336-344
出版商
Wiley
发表日期
2020-01-04
DOI
10.1002/pros.23948
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Interleukin-6 induced overexpression of valosin-containing protein (VCP)/p97 is associated with androgen-independent prostate cancer (AIPC) progression
- (2018) Divya Duscharla et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation
- (2018) Kenichiro Ishii et al. PROSTATE
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
- (2018) Arianna Calcinotto et al. NATURE
- A role for paracrine interleukin‐6 signaling in the tumor microenvironment in prostate tumor growth
- (2018) Shu‐Han Yu et al. PROSTATE
- Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
- (2017) Zoila Lopez-Bujanda et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Neutrophils in cancer: prognostic role and therapeutic strategies
- (2017) Alberto Ocana et al. Molecular Cancer
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer
- (2016) Xiaotao Yin et al. MEDICINE
- Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
- (2015) K L Mahon et al. BRITISH JOURNAL OF CANCER
- A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
- (2015) S.-H. Yu et al. Cancer Immunology Research
- A Peripheral Circulating TH1 Cytokine Profile Is Inversely Associated with Prostate Cancer Risk in CLUE II
- (2014) N. A. Bhavsar et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival
- (2014) Jaya Sharma et al. PROSTATE
- Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group
- (2013) Fernando Calais da Silva et al. EUROPEAN UROLOGY
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells
- (2013) Chengfei Liu et al. PROSTATE
- Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
- (2012) Juanita M. Crook et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer
- (2011) Daniel J. Zabransky et al. PROSTATE
- Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
- (2009) Toni K. Choueiri et al. CANCER
- A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation
- (2009) William D. Figg et al. JOURNAL OF UROLOGY
- Th17 cells in human disease
- (2008) Laura A. Tesmer et al. IMMUNOLOGICAL REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started